23 May 2024 : Database Analysis
MRTO4 Enhances Glycolysis to Facilitate HCC Progression by Inhibiting ALDOB
Yongyuan Zheng1ABCD, Yansong Huang1CDE, Weibing Li1CD, Hongqiu Cheng1AEG*DOI: 10.12659/MSM.944685
Med Sci Monit 2024; 30:e944685
Table 1 Clinical characteristics of the hepatocellular carcinoma patients.
| Characteristics | Low expression of MRTO4 | High expression of MRTO4 | P value |
|---|---|---|---|
| n | 187 | 187 | |
| Pathologic T stage, n (%) | * | ||
| T1 | 112 (30.2%) | 71 (19.1%) | |
| T2 | 35 (9.4%) | 60 (16.2%) | |
| T3 | 32 (8.6%) | 48 (12.9%) | |
| T4 | 6 (1.6%) | 7 (1.9%) | |
| Pathologic N stage, n (%) | 1.000 | ||
| N0 | 125 (48.4%) | 129 (50%) | |
| N1 | 2 (0.8%) | 2 (0.8%) | |
| Pathologic M stage, n (%) | 0.553 | ||
| M0 | 127 (46.7%) | 141 (51.8%) | |
| M1 | 3 (1.1%) | 1 (0.4%) | |
| Pathologic stage, n (%) | * | ||
| Stage I | 103 (29.4%) | 70 (20%) | |
| Stage II | 33 (9.4%) | 54 (15.4%) | |
| Stage III | 33 (9.4%) | 52 (14.9%) | |
| Stage IV | 4 (1.1%) | 1 (0.3%) | |
| Tumor status, n (%) | * | ||
| Tumor free | 112 (31.5%) | 90 (25.4%) | |
| With tumor | 68 (19.2%) | 85 (23.9%) | |
| Gender, n (%) | 0.740 | ||
| Female | 62 (16.6%) | 59 (15.8%) | |
| Male | 125 (33.4%) | 128 (34.2%) | |
| Age, n (%) | 0.570 | ||
| ≤60 | 86 (23.1%) | 91 (24.4%) | |
| >60 | 101 (27.1%) | 95 (25.5%) | |
| BMI, n (%) | * | ||
| ≤25 | 78 (23.1%) | 99 (29.4%) | |
| >25 | 93 (27.6%) | 67 (19.9%) | |
| Histological type, n (%) | 0.117 | ||
| Hepatocellular carcinoma | 182 (48.7%) | 182 (48.7%) | |
| Hepatocholangiocarcinoma (mixed) | 2 (0.5%) | 5 (1.3%) | |
| Fibrolamellar carcinoma | 3 (0.8%) | 0 (0%) | |
| Residual tumor, n (%) | 0.464 | ||
| R0 | 167 (48.4%) | 160 (46.4%) | |
| R1 | 7 (2%) | 10 (2.9%) | |
| R2 | 1 (0.3%) | 0 (0%) | |
| Histologic grade, n (%) | * | ||
| G1 | 35 (9.5%) | 20 (5.4%) | |
| G2 | 102 (27.6%) | 76 (20.6%) | |
| G3 | 46 (12.5%) | 78 (21.1%) | |
| G4 | 1 (0.3%) | 11 (3%) | |
| AFP(ng/ml), n (%) | * | ||
| ≤400 | 124 (44.3%) | 91 (32.5%) | |
| >400 | 26 (9.3%) | 39 (13.9%) | |
| Albumin(g/dl), n (%) | 0.938 | ||
| <3.5 | 38 (12.7%) | 31 (10.3%) | |
| ≥3.5 | 126 (42%) | 105 (35%) | |
| Prothrombin time, n (%) | 0.124 | ||
| ≤4 | 106 (35.7%) | 102 (34.3%) | |
| >4 | 54 (18.2%) | 35 (11.8%) | |
| Child-Pugh grade, n (%) | 0.809 | ||
| A | 120 (49.8%) | 99 (41.1%) | |
| B | 10 (4.1%) | 11 (4.6%) | |
| C | 1 (0.4%) | 0 (0%) | |
| Fibrosis ishak score, n (%) | * | ||
| 0 | 48 (22.3%) | 27 (12.6%) | |
| 1/2 | 14 (6.5%) | 17 (7.9%) | |
| 3/4 | 9 (4.2%) | 19 (8.8%) | |
| 5 | 3 (1.4%) | 6 (2.8%) | |
| 6 | 47 (21.9%) | 25 (11.6%) | |
| Vascular invasion, n (%) | * | ||
| No | 119 (37.4%) | 89 (28%) | |
| Yes | 46 (14.5%) | 64 (20.1%) | |
| Adjacent hepatic tissue inflammation, n (%) | 0.254 | ||
| None | 71 (30%) | 47 (19.8%) | |
| Mild | 50 (21.1%) | 51 (21.5%) | |
| Severe | 11 (4.6%) | 7 (3%) | |
| OS event, n (%) | * | ||
| Alive | 135 (36.1%) | 109 (29.1%) | |
| Bold values indicate * P Statistical analysis was performed by the Pearson χ-test. OS – overall survival. | |||